Suparna Sanyal
Katy,TX
Summary
Innovation and commercialization manager with over 15 years of broad industrial experience spanning CDMO, Pharma, Biotech and Academic Institutions. Possess a unique blend of proven cross-functional global leadership experience coupled with highly technical scientific skills. Led numerous multi-disciplinary teams to develop and deliver customer-focused programs or products aligned with business goals and strategy. Strong background in Cell and Viral Gene Therapy, Exosomes, Stem cells, Neuroscience, Oncology, Pharmacology, Cell Biology and Assay Development. Thoroughly enjoy working in a collaborative team environment, and building lasting relationships. Committed to coaching, mentoring and developing professionals both at work and externally. Excellent at data analysis and organization, strong work ethics, proficient in oral presentations and writing peer reviewed journal articles and reviews.
Overview
25
25
years of professional experience
Work History
Innovation and Commercial Integration Manager
Lonza
Houston, TX
01.2019 - Current
- Systematized Innovation portfolio for the Cell and Gene Technologies business unit in Lonza to enable efficient decision making
- Led global cross-functional multi business unit teams to generate >40 innovation business cases in 9 months
- Responsible for managing stage gate process, documentation to support various stage-gate transition and reports/presentations to senior executives
- Generated competitive landscape analysis, market trend and financial forecast to support innovation projects
- Guided technical, operational and commercial project team to align with goals to deliver customer-focused, viable business offerings for profitable business pipeline and growth
- Monitor consumer and market trends both regionally and globally to identify innovation opportunities in the market to stay ahead vs
- Following trends
- Led technical due diligence of innovation technologies to identify strategic platforms for future growth either through development, partnership or acquisition
Proposals Manager
Lonza
Houston, TX
01.2017 - 12.2019
- Proactively built network with Customers and key functions (Business Development, Commercial Development, Technical Operations SMEs and PMs), Key Opinion Leaders and relevant industry organizations to generate competitive, customer-centric proposals
- Standardized and managed process and queue for proposals and SOWs
- Delivered over 50 proposals/year on time to support sales and revenue targets
- Developed and standardized unit operation, templates and pricing to reduce turnaround time of proposals by 30 to 50%
- Coordinated and chaired customer site visits
- Participated in demand planning to manage cleanroom reservations for new clients to facilitate timely project execution in PD and GMP
- Provided technical training and webinars for Proposals Manager and Business Development Associates
Institute Research Scientist
The Neurodegeneration Consortium (NDC)
Houston, TX
01.2014 - 12.2016
- Company Overview: UT-MD Anderson (IACS)
- In vitro R&D lead for drug discovery pipeline aimed at reducing neurodegeneration and neuro-inflammation in Alzheimer’s disease
- Successfully validated primary target (DLK inhibitor) and transitioned project to lead optimization; this was a critical project which led to creation of the start-up, Magnolia Neurosciences
- Collaborated and guided CROs for external assay development and HTS screening
- Supervised and mentored a team of scientists to generate relevant in vitro disease and screening models for neurodegeneration and neuro-inflammation
- UT-MD Anderson (IACS)
Staff Scientist
BD Biosciences
Bedford, MA
01.2004 - 10.2014
- As Project Manager, led cross-functional core teams for product development using phase gate process following CFR 21.820.30 design control
- R&D Lead on cross-functional product development teams
- Provided strategic and technical guidance to the business development group for cell biology related product and technology roadmap development (focused on stem cells and angiogenesis pipelines)
- R&D Liaison for key external collaborations with (WiCell, StemCell Technologies, Cellartis, Geron, Fate Therapeutics), KOLs in the field of Stem Cells and other business units at BD
- Led technology evaluations/due diligence for new technology implementation in R&D and for new product development
- Set up pluripotent stem cell (hESC and iPSC) culture facility at BD (Bedford, MA); trained associates to bank, culture, characterize and differentiate stem cells
- Used Design for Six Sigma green belt tools for experimental design and project management (Voice of Customer, DOE, process control)
- Led a team of scientists to support product development, performance testing, validation, and application development
- Trained and supervised scientists, sales force and technical support associates across multiple locations at BD
- Trainer for pluripotent stem cell culture at Rutgers University Stem Cell Course
- Published patents, white papers, application notes and presented several webinars and scientific tutorials/presentations at conferences
Postdoctoral Fellow
Astra Zeneca
Boston, MA
01.2001 - 01.2004
- Evaluated the role of specific GPCR and receptor tyrosine kinase (RTK) signaling in development of angiogenesis using in vitro models
- Set up endothelial cell migration and proliferation assays and validated chemotaxis cell migration assay as part of a screening cascade
- Collaborated with Chemistry, Bioinformatics and DMPK to implement this small molecule screening assay
- Characterized pertinent signal transduction pathways utilized by GPCRs and RTKs in mediating angiogenesis using RT-PCR, pathway inhibitors, phosphorylation analysis and other cell based assays (e.g
- Immunohistochemistry, IP, western blots)
- Independently conceived and implemented a proposal to study GPCR hetero-dimerization, trafficking, co-localization and protein-protein interaction using immunofluorescence, FRET and confocal microscopy
- Developed a functional screen using FLIPR-based calcium mobilization to identify compounds that could discriminate between GPCR heterodimers vs homodimers
- Set up radioligand binding assays and documented receptor density and ligand affinity at opioid receptors using cell membrane preps and whole cells
- Supervised research associates for the GPCR hetero-dimerization project
Education
Ph.D. - Pharmacology
University of Toronto
01.2002
M.Sc. - Pharmacology
University of Toronto
01.1995
B.Sc. (Honours) - Pharmacology and Toxicology
University of Toronto
01.1993
Skills
- Innovation Portfolio Management
- Strategic Pipeline Development
- Technical Due Diligence
- Commercial Development
- Marketing
- Proposals
- Project Management
- Product Development
- Business Development
- Drug discovery
- Neuroscience
- Pharmacology
- Stem Cells
- Cell Biology
- Assay Development
Training
- Leadership Development Plan, BD University, 01/01/09
- Design for six sigma for product development, BD University, 01/01/09
- Managing for Performance Excellence, BD University, 01/01/08
- Project management using Global Product Development System (GPDS), BD University, 01/01/08
- BD Biosciences Coaching and Mentoring Program, BD University, 01/01/06
- Project Management Mastery using Microsoft Project, BD University, 01/01/05
- Human ES Cell Culture 10-day Workshop, CHOC, Orange County, CA, 04/01/05
Publications
- Culture and Assay Systems Used for 3D Cell Culture (White Paper Review), Sanyal, S., 2014, Corning, http://bit.ly/3Dcellculturearticle
- Scaling up cells in Falcon Cell Culture Multi-Flasks, Sanyal, S., Abraham, E., Slater, K., Cai, A., Lacey, B., Hartshorn, C., Flaherty, P., McHugh, B., Qian, S., 2011, Corning, App Note # 489
- Scale-up of mammalian cell culture using a new Multi-layered Flask, Abraham, E., Slater, K., Sanyal, S., Linehan, K., Flaherty, P., Qian, S., 2011, Journal of Visualized Experiments, 58, 3418-3422
- BD PureCoat surfaces: Development of two novel culture surfaces that enhance cell performance in cell-based assays, Abraham, E. J., Partridge, J., Sanyal, S., Saxena, D., Qian, S., 2009, BD Biosciences, App Note #466
- BD Matrigel Matrix: A proven substrate for feeder-free culture of human embryonic stem (hES) cells, Sanyal, S., Qian, S., 2006, Science: Stem Cells Collection, A booklet from Science, produced by the AAAS, p32-33
- Optimized chemotaxis conditions for primary blood monocytes of THP-1 cell using BD Falcon FluoroBlok 96 Multiwell insert plates, Sanyal, S., Qian, S., 2005, BD Biosciences, Technical Bulletin # 457
- Dopamine modulates the plasticity of mechanosensory responses in C. elegans, Sanyal, S., Wintle, R. F., Kindt, K. S., Nuttley, W. M., Arvan, R., Fitzmaurice, P., Bigras, E., Merz, D. C., Hebert, T. E., van der Kooy, D., Schafer, W. R., Culotti, J. G., Van Tol, H. H. M., 2004, EMBO, 23, 2, 473-82
- Potential therapeutic targets for schizophrenia (Review), Wong, A. H. C., Sanyal, S., Knapp, M., Van Tol, H. H. M., 1999, Emerging Therapeutic Targets, 3, 4, 1-16
- Dopamine D2 and D4 receptor ligands: relation to antipsychotic action (Review), Wilson, J. M., Sanyal, S., Van Tol, H. H. M., 1998, European Journal of Pharmacology, 351, 3, 273-86
- Dopamine D4 receptor-mediated inhibition of cAMP production does not affect prolactin regulation, Sanyal, S., Van Tol, H. H. M., 1997, Endocrinology, 138, 5, 1871-1878
- The role of dopamine D4 receptors in schizophrenia and antipsychotic action (Review), Sanyal, S., Van Tol, H. H. M., 1997, Journal of Psychiatric Research, 31, 2, 219-232
- Cryptic initiation at the human D4 receptor reveals a functional role for the amino-terminus, Schoots, O., Sanyal, S., Guan, H.-G., Jovanovic, V., Van Tol, H. H. M., 1996, Biochemistry, 35, 3614-3618
- Dopamine D4 receptor variant in Africans, D4Valine194Glycine, is insensitive to dopamine and clozapine. Report of a homozygous individual, Liu I. S. C., Seeman, P., Sanyal, S., Ulpian, C., Rodgers-Johnson, P. E. B., Serjeant, G. R., Van Tol, H. H. M., 1996, American Journal of Medical Genetics, 61, 3, 277-282
- Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants, Asghari, V., Sanyal, S., Buchwaldt, S., Paterson, A., Jovanovic, V., Van Tol, H. H. M., 1995, Journal of Neurochemistry, 65, 1157-1165
Intellectualproperty
- Qian, S. X., Sanyal, S., Becton, Dickinson and Company, 08/12/12, Extracellular Matrix Coated Surface for Culturing Cells, US8,241,908
- Sanyal, S., Saxena, D., Qian, S. X., Abraham, E., Becton, Dickinson and Company, 01/28/10, Defined Cell Culturing Surfaces and Methods of Use, US2010/00211998 A1
Timeline
Innovation and Commercial Integration Manager
Lonza
01.2019 - Current
Proposals Manager
Lonza
01.2017 - 12.2019
Institute Research Scientist
The Neurodegeneration Consortium (NDC)
01.2014 - 12.2016
Staff Scientist
BD Biosciences
01.2004 - 10.2014
Postdoctoral Fellow
Astra Zeneca
01.2001 - 01.2004
Ph.D. - Pharmacology
University of Toronto
M.Sc. - Pharmacology
University of Toronto
B.Sc. (Honours) - Pharmacology and Toxicology
University of Toronto